| Description |
PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research[1][2][3].
|
| Related Catalog |
|
| In Vitro |
PNC-27 (50 μg/mL; 0-3 h) induces cancer cell death[1]. PNC-27 (50 μg/mL; 15 min) binds to cell membrane-bound HDM-2[1]. Cell Cytotoxicity Assay[1] Cell Line: MIA-PaCa-2 cells Concentration: 50 μg/mL Incubation Time: 0-3 hours Result: Induced 100% cell death in 90 min. Immunofluorescence[1] Cell Line: A2058 and MCF-7 cells Concentration: 50 μg/mL Incubation Time: 15 min Result: Showed colocalization of PNC-27 with HDM-2 in the cancer cell membrane.
|
| In Vivo |
PNC-27 (intraperitoneal injection; 40 mg/kg; once daily; 2-3 w) shows anti-leukemia activity in vivo[2]. Animal Model: MllPTD/WT/Flt3ITD/ITD AML mice[2] Dosage: 40 mg/kg Administration: Intraperitoneal injection; 40 mg/kg; once daily; 2 or 3 weeks Result: Observed reduced AML engraftment and prolonged survival.
|
